Atrion Corporation Stock

Equities

ATRI

US0499041053

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-04-19 pm EDT 5-day change 1st Jan Change
402.4 USD +4.32% Intraday chart for Atrion Corporation +0.75% +6.22%
Sales 2022 184M Sales 2023 169M Capitalization 667M
Net income 2022 35M Net income 2023 19M EV / Sales 2022 5.27 x
Net cash position 2022 25.21M Net cash position 2023 6.02M EV / Sales 2023 3.9 x
P/E ratio 2022
28.6 x
P/E ratio 2023
34.4 x
Employees 712
Yield 2022
1.47%
Yield 2023
2.3%
Free-Float 39.7%
More Fundamentals * Assessed data
Dynamic Chart
1 day+4.32%
1 week+0.75%
Current month-13.20%
1 month-6.12%
3 months+19.53%
6 months+13.34%
Current year+6.22%
More quotes
1 week
381.31
Extreme 381.31
412.89
1 month
374.84
Extreme 374.835
468.00
Current year
308.30
Extreme 308.3
468.00
1 year
274.98
Extreme 274.98
670.00
3 years
274.98
Extreme 274.98
805.62
5 years
274.98
Extreme 274.98
922.80
10 years
274.98
Extreme 274.98
948.03
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 04-12-31
Director of Finance/CFO 49 21-06-13
Members of the board TitleAgeSince
Director/Board Member 74 84-12-31
Director/Board Member 74 17-03-12
Chairman 86 86-12-31
More insiders
Date Price Change Volume
24-04-19 402.4 +4.32% 38,766
24-04-18 385.7 -3.28% 25,747
24-04-17 398.8 -2.53% 35,436
24-04-16 409.1 +2.62% 22,594
24-04-15 398.7 -0.17% 22,273

Delayed Quote Nasdaq, April 19, 2024 at 04:00 pm EDT

More quotes
Atrion Corporation develops and manufactures products, primarily for medical applications. The Company's medical products are used in a number of fields including fluid delivery, cardiovascular, and ophthalmic applications. It has developed a variety of proprietary valves designed to precisely fill, hold, and release and/or remove controlled amounts of fluids, including blood and drugs, or gasses on demand for use in areas such as intubation, intravenous, catheter, and other applications in fields including anesthesia and oncology. The core of its cardiovascular products is its Myocardial Protection System, a technology that is the only open-heart surgery system that delivers to the heart essential fluids and medications, mixes critical drugs, and controls temperature, pressure, and other important variables. The Company also manufactures a line of balloon catheters used in the treatment of nasolacrimal duct obstruction in children and adults.
Related indices
More about the company